key: cord-1056507-9bzq9ib1
authors: Spampinato, Michele Domenico; Sposato, Andrea; Migliano, Maria Teresa; Gordini, Giovanni; Bua, Vincenzo; Sofia, Soccorsa
title: Lung Ultrasound Severity Index: Development and Usefulness in Patients with Suspected SARS-Cov-2 Pneumonia. A Prospective Study
date: 2021-08-31
journal: Ultrasound Med Biol
DOI: 10.1016/j.ultrasmedbio.2021.08.018
sha: 11e7db70d56c9e1ec9dbc6069c8871a15c3b1bdd
doc_id: 1056507
cord_uid: 9bzq9ib1

COVID-19 spreads across the world with a strong impact on populations and health systems. Lung Ultrasound is increasingly employed in clinical practice but a standard approach and data about the accuracy of Lung Ultrasound are still needed. Our study's objective is to evaluate Lung Ultrasound diagnostic and prognostic characteristics in patients with suspected COVID-19. We conducted a monocentric, prospective, observational study. Patients with respiratory distress and suspected COVID-19 consecutively admitted in the Emergency Medicine Unit were enrolled. Lung Ultrasound examinations were performed blindly to clinical data. Outcomes were diagnosis of COVID-19 pneumonia and in-hospital mortality. 159 patients were included in our study, 66% were males and 63.5% had a final diagnosis of COVID-19. COVID-19 patients had a higher mortality rate (18.8% vs 6.9%, P=.04) and Lung Ultrasound Severity Index (16.14 [8.71] vs 10.08 [8.92], P<.001) compared to non-COVID-19 ones. This model proved able to distinguish between positive cases from negative ones with an Area Under the Receiver Operating Characteristic (AUROC) equal to 0.72 (95% CI 0.64-0.78) and to predict in-hospital mortality with an AUROC equal to 0.81 (95% CI 0.74-0.86), in the whole population, and an AUROC equal to 0.76 (95% CI 0.66-0.84) in COVID-19 patients. Lung Ultrasound Severity Index can be a useful tool in diagnosing COVID-19 in patients with a high pretest probability to have the disease and - among them - identify those with worse prognosis.

Coronavirus associated disease 2019 (COVID-19) encompasses a wide range of clinical manifestations due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a novel human Betacoronavirus first isolated in December 2019 in Wuhan, China (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020). Since then, SARS-CoV-2 infection has rapidly spread across the world and on January 30th, 2020, the World Health Organization declared the International Public Health Emergency (World Health Organization, 2020). The pandemic had a huge impact on health systems and people of affected countries, causing a strong increase in demand for care and heavy social and economic consequences. Although SARS-CoV-2 has pleiotropic actions (Gupta et al. 2020) , its main target is the lung.

Through initial alveolar damage, the infection can result in mild, moderate, or severe pneumonia. Therefore, chest imaging, and in particular Computerized Tomography (CT), became a milestone in the diagnosis of COVID-19 (Han et al. 2020) , especially in the early stages of the pandemic, due to the poor availability and reliability of microbiological diagnostic tests (Wyllie et al 2020 , Zitek 2020 . Nevertheless, its high costs and ionizing radiations limit the use of chest CT mainly in the monitoring of pneumonia (ACR 2020). Moreover, in many countries, CT is not widely available. Lung Ultrasound (Lung US), having an acknowledged role in the diagnosis and staging of many lung diseases (Volpicelli et al. 2012) , has been repeatedly evoked as a potentially useful tool in the context of the current pandemic and has been included in many clinical diagnostic pathways of SARS-CoV2 pneumonia. Latest reports (Bonadia et al. 2020 , Dargent et al. 2020 , Lu et al. 2020 , Sofia et al. 2020 , Tan et al. 2020 , Vetrugno et al. 2020 , Xing et al. 2020 , Yasukawa et al. 2020 claim its beneficial use in such a context. However, published studies are generally based on score systems that do not consider the patchy US appearance of SARS-CoV-2 pneumonia, due to the different patterns displayed in the same area. In our opinion, this issue could be relevant to better assess Lung US diagnostic characteristics in SARS-CoV-2 pneumonia.

This study aims to propose and validate the "Lung Ultrasound Severity Index" (LUSI), a novel ultrasound score designed to measure the quality and extent of lung involvement, in relation to diagnosis and in-hospital mortality of patients with respiratory distress admitted for suspected COVID-19.

This is an observational prospective study. All patients consecutively admitted to our Emergency Medicine Unit (EMU) between March 6, 2020, and April 5, 2020, for suspected COVID-19 as the main disease and age > 18 years underwent a standard Lung US examination and were included in our study if informed consent was given. According to our institutional protocol, a "suspected COVID-19" is a patient with respiratory distress, fever, cough, anosmia, or dysgeusia with or without lung abnormalities, in which SARS-CoV-2 infection is a possible cause of the clinical picture. The study was conducted in accordance with the Declaration of Helsinki. All Lung US examinations were acquired and interpreted individually by an Emergency Medicine Physician or an Emergency Medicine resident, both with at least 5 years of experience in emergency ultrasound, including chest ultrasound. Patients admitted to EMU during the working hours of one of the two operators were recruited for the present study. The local institutional ethics committee approved the study protocol. In each patient, a Lung US examination was performed at admission to EMU, blind to clinical, radiological, and laboratory data. Then Lung US records acquired by one of the two operators were reviewed blindly by the other to assess inter-observer variability. Past medical records, vital signs, laboratory findings, and in-hospital death of the included patients were retrospectively collected.

Clinical presentation, vital signs, and laboratory data refer to the admission in the Emergency Department (ED). Anion blood gas analysis (ABGA) was the closest to the Lung US examination, at most 8 hours before or later. COVID-19 is a microbiological diagnosis. The diagnostic standard was the RT-PCR assay to detect SARS-CoV-2 RNA on the nasopharyngeal swab. If the swab was not diagnostic and high suspicion of COVID-19 persisted, it was repeated at least three times. Patients with repeated negative swabs, low clinical suspicion, and another underlying cause of respiratory distress were considered COVID-19 negative.

Lung Ultrasound Scanning technique: Included patients received a standard Lung US examination as follows: three areas were defined for each hemithorax, bounded by the sternal marginal line, the anterior axillary, the posterior axillary, and the dorsal marginal one. Each area was further subdivided into upper and lower sectors, delimited by the third intercostal space in front and side areas, and by the lower scapular edge in the posterior ones. So, 12 thoracic areas were defined, numbered from 1 to 6 according to the chest side (Fig. 1) . The whole extension of all areas was scanned, moving the probe with a continuous movement from border to border. Patients were examined in a sitting position. At least a 6-second video was recorded for each of the 12 areas defined above.

All scans were performed using equipment ESAOTE MyLab XPRO30 (Esaote, Via E. Melen, 77 16152 Genova, Italia) with a convex probe at 10±3 cm scan depth focused on the pleural line. The convex probe is the most common in the Emergency Departments and enables exploration of large thoracic areas. Moreover, a less frequency probe, reducing ultrasound attenuation, allows better visualization of all the lung ultrasonographic findings, from A-lines to major parenchymal consolidation and pleural effusion. During the Lung US examinations all locally indicated personal protective equipment was used, including a disposable cap, a filtering facepiece 2 (FFP2), a protective suit, 2 pairs of disposable latex gloves, and disposable shoe covers. The facility was sanitized before and after each exam with a 0.05% sodium hypochlorite solution.

Main ultrasound findings (A-lines, B-lines, and consolidations) were defined according to the International Consensus Conference on Lung Ultrasound (Volpicelli 2012) . After each scan, all findings were recorded according to the examined area in a Lung US datasheet. Each finding accounted for a different score, to measure various degrees of alveolar aeration impairment, as follows:

-A-pattern: A-lines without other artifacts, 0 points ( Fig. 2) -Isolated B-lines: one or no more than three distant, well-isolated B-lines, 1 point (Fig. 3) -Isolated subpleural consolidation: in a context of A-pattern, presence of one consolidation <2 cm with a posterior vertical artifact, extending to the bottom of the screen without fading, and moving synchronously with lung sliding, 1.5 points (Fig. 4) -Non-confluent B-lines: multiple B-lines that do not completely erase A-lines, 2 points (Fig. 5 ).

-Confluent B-lines: multiple B-lines that completely erase A-lines, 3 points (Fig. 6 ).

-Confluent Subpleural Consolidations (CSpCs): multiple consolidations <2 cm in depth with a posterior vertical artefact, 4 points (Fig. 7) .

-Parenchymal consolidation >2 cm: subpleural consolidation >2 cm in-depth, 5 points (Fig. 8 ).

-Pleural effusion: anechoic fluid within the pleural space, 0 points ( Fig. 9 ).

Lung Ultrasound Severity Index:

Scores of each area were added to calculate a regional Lung Ultrasound Severity Score (rLUSS). The Lung Ultrasound Severity Score (LUSS) was obtained by summing all rLUSS values. The number of different ultrasound patterns found in each area defined the regional Lung Ultrasound Heterogeneity Score (rLUHS). The regional Lung Ultrasound Severity Index (rLUSI) was computed as rLUSS/rLUHS for each area. Finally, the Lung Ultrasound Severity Index (LUSI) was calculated as the sum of all rLUSI, and the Lung Ultrasound Heterogeneity Score (LUHS) was calculated as the sum of rLUHSs. See Tab. 1 for the LUSI record sheet and calculator.

Normally distributed data were described as mean and standard deviation (SD); not normally distributed data were described as the median and interquartile range (IQR); categorical data were reported as absolute number and percentage. Normally distributed data were compared via independent sample t-test.

Not normally distributed data were compared via Mann-Whitney Test U. Pearson"s chi-square test was used to compare categorical dependent variables among at least 2 independent groups. The correlation between two independent parametric continuous variables was determined using Pearson"s correlation. The receiver operator characteristic (ROC) curves were determined for the relationship of LUSS, LUHS, and LUSI with the severity of pneumonia. The optimal threshold for best discrimination was calculated using the Youden index. Inter-observer reliability of LUSI was assessed with Cohen"s Kappa. Statistical analyses were performed using SPSS v.23 (Apache Software Foundation, Chicago, Illinois, USA) and MedCalc, version 14.8.1 for Windows, MedCalc Software Ltd.

Clinical characteristics of all patients: 159 patients were included in the study, mean age was 64.6 years and males were 66%. 49% had a respiratory failure (P/F ratio ≤300 mmHg) at admission. 63.5% of patients were positive to standard test RT-PCR for SARS-CoV-2 and had a final diagnosis of COVID-19. ABGAs revealed higher values of pH and lower levels of pCO2 and P/F ratio in the COVID-19 group (Table 2) . 23 (14,5%) of included patients died during the study lag, 19 (82%) of them coming from the COVID-19 group. Among COVID-19 patients, those who died were older, with higher heart rate, higher respiratory rate, and lower blood oxygenation at presentation compared to survivors COVID-19 patients.

Lung Ultrasound Characteristics of all patients:

The included patients resulted in 3779 total 6-seconds videos recorded, with a mean value of 23.8 videos for each patient. while no significant differences were found in LUHS (Table 2) . Moreover, both LUSI and LUSS showed a strong inverse correlation with P/F, with a Pearson"s r of -0.61 (p < .001) and -0.599 (p <.001), respectively, while LUHS showed a weak correlation with P/F (-0.386, p < .001). In relation to the diagnosis of COVID-19, LUSI had an AUROC of 0.72 (95% CI 0.64-0.78) with 63% sensitivity and 75% specificity for LUSI > 13 (the best single cut-off), a sensitivity of 95% for a LUSI > 2 and a specificity of 95% for a LUSI > 26.

However, no differences were noted in LUSI"s, LUSS", and LUHS" AUROCs (see Table 3 ).

Related to in-hospital mortality, LUSI had the best AUROC, equal to 0.81 (95% CI 0.73-0.86), significantly greater than LUSS (difference between AUROC equal to 0.062, P = .004) and LUHS (difference between AUROC of 0.177, P < .001). LUSI has an OR of 1.14, suggesting an increase of 14% in mortality risk for each point. The best Youden Index was associated with a cut-off of 14.5, with sensitivity and specificity of 90% and 65.67% respectively, while a cut-off of 4 had 95% sensitivity and a cut-off of 26 had 95% specificity.

In-hospital death related to Lung Ultrasound Characteristics in patients with COVID-19

The number of acquired scans and length of ultrasound examination were similar in patients with COVID-19 who died during in-hospital stay and survivors. COVID-19 patients who died had a lower number of areas with A-pattern and a higher number of areas with non-confluent B-lines, confluent B-lines, and CSpCs.

LUSI and LUSS were also higher in dead COVID-19 patients than in the survivors, but no differences were found in LUHS. Considering only the patient population with the final diagnosis of COVID-19, LUSI, LUSS and LUHS correlate with the P/F ratio impairment, even when data were adjusted for comorbidities, (Pearson"s r of -0.613, P < .001, -0.569, P < .001 and -0.284 P = .01 respectively). LUSI had the best AUROC for in-hospital mortality, equal to 0.76 (95% CI 0.66 -0.84), significantly greater than LUSS (difference between AUROCs of 0.07 P = 0.018) and LUHS (difference between area equal to 0.18, P = .001). LUSI had an OR of 1.124, with an increase of 12.4% in mortality risk for each point of LUSI. The best Youden Index was associated with a cut-off of 24, with sensitivity and specificity of 63.16% and 90.12% respectively and LR + of 6.7, while a cut-off of > 0 had 95% sensitivity and a cut-off of 30 had 95% specificity.

All Lung US data are enlisted in Tab. 2 and 3.

Our study population is similar to those of other reports , Goyal et al. 2020 . Although many laboratory markers of inflammation are strongly correlated with COVID-19 diagnosis and in-hospital mortality and only some Lung US signs do the same, neither laboratory nor US signs, if individually evaluated, can correctly establish a final diagnosis. Just the integration of different clinical, laboratory and US features could suggest the correct diagnosis, as demonstrated for many diseases (i.e., pulmonary edema, ARDS, bacterial or viral causes of pneumonia, contusions, and others), where a similar loss of aeration in subpleural air spaces generate the same US signs. In lung diseases, a typical distribution and the association of different Lung US or patterns could suggest the presence of a definite disease (Volpicelli et al. 2012 , Bekgoz et al. 2019 , Weile et al. 2020 , Copetti et al. 2008 .

Several authors have argued that Lung US is potentially helpful in distinguishing between COVID-19 and non-COVID-19 patients in the Emergency Departments (Tan et al. 2020 , Narinx et al 2020 , Bar et al. 2020 with a high interobserver agreement (Yassa et al. 2020) , representing a valid diagnostic aid in the management of patients with COVID-19 pneumonia (Dargent et al. 2020 , Nouvenne et al. 2020 , Zieleskiewicz et al. 2020 , also potentially able in reducing the number of healthcare providers exposed to possible contamination (Mongodi et al. 2020 ).

Recently Islam et al. (Islam 2021) reported an 86,4% (95% CI 72.7 to 93.9) ultrasound pooled sensitivity and a 54.6% (95% CI 35.3 to 72.6) ultrasound pooled specificity for the diagnosis of COVID 19 pneumonia.

Moreover, they emphasize that data required to properly evaluate the diagnostic performance of various RT-PCR testing is used to diagnose a current infection, but its utility as a reference standard is constrained by its limited sensitivity (71% to 98%). Chest CT is being widely used in the setting of suspected and confirmed cases of COVID-19; however, a recent Cochrane Systematic Review reported a pooled sensitivity equal to 87.9% (95% CI 84.6 -90.6) and specificity equal to 80% (95% CI 74.9 -84.3) for the diagnosis of SARS-CoV-2 pneumonia. According to the authors of the Systematic Review, these findings indicate that HRCT is not able to differentiate COVID-19 from other causes of respiratory illness (Islam 2021 ). An interesting observation came from Mongodi (2017) whereby "the coalescence of B lines alone to define the severe loss of aeration is not suitable for non-homogeneous lung pathologies (ARDS, contusion), potentially leading to overestimation of aeration loss by Lung US, thus suggesting that a modified and more detailed Lung US scoring system could be more appropriate in such and similar diseases. Moreover, as already reported by Volpicelli et al, a semi-quantitative approach to the definition of lung involvement on Lung US is more precise than a qualitative one (Volpicelli 2012 ) that evaluates only the presence of the worst pulmonary abnormality in each thoracic area.

Moving from these considerations, we decided to build a Lung US model that could semi-quantitatively represent the extent of lung involvement and could include the typical patchy appearance of SARS-CoV-2 pneumonia, reporting clearly all data regarding the technical aspect of the Lung US examination, all data regarding the accuracy of the model, and testing it only in regard to the RT-PCR results, the only universally accepted standard reference for the diagnosis of COVID-19.

In our study, A-Pattern and Confluent Subpleural Consolidations were the two pulmonary signs that most differed in distribution between COVID-19 and non-COVID-19 patients, the former being most common in non-COVID-19 and survived patients and the latter in COVID-19 and deceased patients. B-lines in various degrees and aggregations did not differ in COVID-19 patients compared to non-COVID-19 ones; however, B-lines are more widespread in COVID-19 patients who died. That could be explained by larger alveolar damage in these patients, due to both infection (as in early phases of disease) and cytokine storm, possibly enhanced by coexisting comorbidities. As the inflammation progresses, B-lines areas complicate with the appearance of subpleural thicknesses as Confluent Subpleural Consolidations. Conversely, consolidations larger than 2 cm are infrequent and do not differ significantly between groups, thus appearing not related to COVID-19 aetiology.

Even if early B-lines or coalescent B-lines alone could not be able to distinguish between COVID-19 and non-COVID-19 patients, their irregular distribution throughout the lung along with Confluent Subpleural Consolidations may reflect the patchy distribution of SARS-CoV-2 pneumonia as a diffuse pulmonary inflammatory syndrome at different stages of evolution and probably set up the elements enabling our LUHS"s and LUSI"s capacity to distinguish among COVID-19 and non-COVD-19 patients.

The goal of LUSI is to better describe the coexistence of different lung lesions in the same lung area: in this way we have shown that this new scoring system, therefore considering the coexistence of higher severity lesions with the presence of A-pattern areas, can better discriminate between patients with COVID-19 and not, and considering only the COVID-19 patients, better identifies patients who will experience in-hospital mortality when compared to LUSS, the simple sum of the lung US findings. LUHS is the sum of the number of different US patterns found in each area: again, a simple but straightforward way to measure the typical "patchy distribution" of SARS-CoV-2 pneumonia. LUSI puts together the strengths of both LUSS and LUHS, allowing for a better prognostic ability, as demonstrated by the significantly higher AUROC value of LUSI. Moreover, the inclusion of this type of evaluation, if on one hand slightly complicates the calculation of the score, on the other hand, it includes and enriches the information coming from the different lung patterns. The dichotomous use of the scores allows easier use of them, however, LUSI can provide a lot of information along with the whole range of possible values regarding both the risk of COVID-19 and the short-term prognosis at the same time: in patients with possible COVID-19, a LUSI < 2 as a -LR of 0.25 for COVID-19 diagnosis and a -LR of 0.29 for in-hospital mortality excluding both in low pretest risk patients.

Vice versa, a patient with LUSI = 14, as a + LR of 2.35 for COVID-19 and a + LR of 2.3 for in-hospital mortality telling us that our patient has a significantly higher risk of COVID-19 and poor prognosis.

This study has several limitations. The monocentric nature influences the mortality rate due to our local diagnostic and therapeutic algorithms. The study design was prospective and blinded only in collecting Lung US findings, while clinical data were recorded retrospectively. However, examiners could not be considered fully blinded to the patients: patients were admitted in the EMU only if suspected COVID-19, configuring a population with a high probability of COVID-19. Moreover, respiratory patterns and vital signs were visible to the examiners, who were blinded to clinical histories and diagnostic studies performed.

We considered ABGAs closest to LUS examination, but also a few hours of oxygen support and ventilation could modify the P/F ratio. All lung examinations were made by clinicians experienced in Lung US and the evaluation of intra-observer variability is lacking. Finally, due to the lack of a standard of reference for Lung US evaluation of SARS-CoV2 pneumonia in the conducting, reporting, and grading the degree of pulmonary involvement on Lung US, the score attributed to each Lung US findings and the way to calculate LUSI was decided arbitrarily by the authors. Moreover, the correspondence between Lung US findings and chest CT was not evaluated.

According to our results, LUSI has high diagnostic accuracy in respect to COVID-19 diagnosis and prognosis in both broad populations of patients with suspected COVID-19 and considering only COVID-19

patients. In such an epidemiological scenario, in which a huge number of patients are admitted for the same disease, early differentiation of patients with highly infectious disease from patients with other causes of respiratory distress is essential. While laboratory exams, nasopharyngeal swabs, and HRCT could take several hours to give fundamental information, Lung US could be performed in less than 10 minutes and LUSI could identify patients at higher risk of both COVID-19 disease and in-hospital mortality, to making better decisions about further imaging, urgent therapies, and patient"s destination. Our study was performed in an EMU with a clear diagnostic and therapeutic protocol, further studies are needed to understand LUSI"s role for different clinical goals, such as monitoring of treatment or progression of the disease, or other epidemiological and medical settings. 1) Each column identifies a specific thoracic area: sign in each empty box all the lung ultrasound lesion(s) found in each area. 2) Calculate 1) rLUSS: sum the corresponding points of all patterns found in each area;

2) rLUHS: count of different patterns found in each area; 3) rLUSI: rLUSS/rLUHS 3) LUSI: sum of all rLUSI. Areas with A-pattern, median (IQR), N 11 (10-12) 12 (11-12) 11 (9-12) .01 11 (10-12) 9 (6.75-11) <.001

Areas with isolated B-lines, median (IQR), N 2 (1-4) 2 (0.75-4) 2 (1-4) .46 3 (1-5) 1 (0.75-4) .053

Areas with isolated subpleural consolidations, median (IQR), N 1 (0-2) 1 (0-2) 1 (0-2) .095 2 (0-3) 0 (0-2) .107

Areas with non-confluent B-lines, median (IQR), N 0 (0-2) 0.5 (0-2) 0 (0-2) .85 0 (0-2) 2 (0-3.25) .04

Areas with confluent B-lines, median (IQR), N 0 (0-1.25) 0 (0-0.25) 0 (0-2) .014 0 (0-1) 1.5 (0-3) .013

Areas with Confluent Subpleural Consolidations median (IQR), N 4 (2-6) 2 (0-4) 5 (3-7) < .001 5 (3-6) 6.5 (4.75-8.25) .014

Areas with pulmonary consolidation > 2 cm, median (IQR), N 0 (0-1) 0 (0-1) 0 (0-1) .89 0 (0-1) 0 (0-1.25) .56

Areas with pleural effusion, median (IQR), N 0 (0-1) 0 (0-1.5) 0 (0-1) .38 0 (0-1) 1 (0-2 

ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection

The association of lung ultrasound images with COVID-19 infection in an emergency room cohort

BLUE protocol ultrasonography in Emergency Department patients presenting with acute dyspnea

Lung Ultrasound Findings Are Associated with Mortality and Need for Intensive Care Admission in COVID-19 Patients Evaluated in the Emergency Department

Chest sonography: a useful tool to differentiate acute cardiogenic pulmonary edema from acute respiratory distress syndrome

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Lung ultrasound score to monitor COVID-19 pneumonia progression in patients with ARDS

Clinical Characteristics of Covid-19 in

Extrapulmonary manifestations of COVID-19

Diagnostic accuracy of point-ofcare lung ultrasound in COVID-19

Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia

Thoracic imaging tests for the diagnosis of COVID-19

Lung ultrasound predicts clinical course and outcomes in COVID-19 patients

Lung ultrasound score in establishing the timing of intubation in COVID-19 interstitial pneumonia: A preliminary retrospective observational study

CLUE: COVID-19 lung ultrasound in emergency department

Modified Lung Ultrasound Score for Assessing and Monitoring Pulmonary Aeration

Lung Ultrasound in Patients with Acute Respiratory Failure Reduces Conventional Imaging and Health Care Provider Exposure to COVID-19

Feasibility of using point-ofcare lung ultrasound for early triage of COVID-19 patients in the emergency room

Lung Ultrasound in COVID-19 Pneumonia: Correlations with Chest CT on Hospital admission

Lung ultrasound in the emergency department -a valuable tool in the management of patients presenting with respiratory symptoms during the SARS-CoV-2 pandemic

Thoracic ultrasound and SARS-COVID-19: a pictorial essay

Proposal for International Standardization of the Use of Lung Ultrasound for Patients With COVID-19: A Simple, Quantitative, Reproducible Method

Use of Lung Ultrasound to Differentiate Coronavirus Disease 2019 (COVID-19) Pneumonia From Community-Acquired Pneumonia

The utility of lung ultrasound in COVID-19: A systematic scoping review

Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19

International evidence-based recommendations for point-of-care lung ultrasound

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Point-of-care ultrasound induced changes in management of unselected patients in the emergency department -a prospective single-blinded observational trial

World Health Organization. Situation report n°51

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

Lung ultrasound findings in patients with COVID-19 pneumonia

Lung ultrasonography in pregnant women during the COVID-19 pandemic: an interobserver agreement study among obstetricians

Point-of-Care Lung Ultrasound Findings in Patients with COVID-19

Lung Ultrasound Score in Evaluating the Severity of Coronavirus Disease 2019 (COVID-19) Pneumonia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Comparative study of lung ultrasound and chest computed tomography scan in the assessment of severity of confirmed COVID-19 pneumonia

The Appropriate Use of Testing for COVID-19

Acknowledgements: Soccorsa Sofia takes responsibility for the content of the manuscript. All authors substantially contributed to the design of the work and the acquisition of data. Michele Domenico Spampinato analysed the data, while Soccorsa Sofia, Giovanni Gordini, and Vincenzo Bua take responsibility for the integrity of the data and the accuracy of the data analysis. Michele Domenico Spampinato, Maria Teresa Migliano, and Soccorsa Sofia drafted the work and all the authors revised it critically for important intellectual content, and questions related to the accuracy and integrity of any part of the work were investigated and resolved. All authors approved the final version of the manuscript.

No financial support was provided in conducting this study.The authors have no conflict of interest.